

30 Mar 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260327639180/en/Ollin-Biosciences-Announces-Final-Data-From-Randomized-Head-to-Head-Study-of-OLN324-Compared-to-Faricimab-Vabysmo-in-Wet-Age-Related-Macular-Degeneration-and-Diabetic-Macular-Edema